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Background: Sudden cardiac death resulting from acute myocardial infarction (AMI) constitutes a significant
percentage of the caseload for forensic and clinical pathologists. When sudden death occurs at an early stage
(<6 h), pathologists experience difficulty in the postmortem diagnosis of AMI. Because of the specific tissue
distribution of S100A1 and its relationship with acute ischemic heart disease, this study aimed to evaluate the
performance of S100A1 in the postmortem diagnosis of AMI.
Methods: We constructed a rat model of AMI through permanent ligation of the left anterior descending coronary
artery (LAD) to investigate the depletion of S100A1 from ischemic cardiomyocytes by immunohistochemistry and
measuring S100A1 plasma concentrations by enzyme-linked immunosorbent assay at varying post-infarction
intervals. In addition, immunohistochemical staining of S100A1 for definite infarction, suspected early infarction, and
in normal human hearts, was also performed to test its practical feasibility for postmortem diagnosis of AMI at an
early stage.
Results: As early as 15 min after ligation of the LAD, depletion of S100A1 was observed in ischemic
cardiomyocytes, and S100A1 plasma concentration was also significantly higher than that of the sham-operated
group (P < 0.001). With continuation of the occlusion time, the depleted areas of S100A1 further expanded and
S100A1 plasma concentrations further increased. For autopsy material, all human cases of definite myocardial
infarction and suspected early infarction showed well-defined areas without S100A1 staining. None of the normal
human cases showed diffuse depletion of S100A1.
Conclusion: Our results suggest that immunohistochemical detection of S100A1 is useful for the postmortem
diagnosis of AMI at an early stage.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/4366650979519818
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Sudden cardiac death (SCD) is most commonly defined as
unexpected death from a cardiac cause within a limited
time period, generally <1 h from symptom onset [1]. SCD
resulting from acute myocardial infarction (AMI) consti-
tutes a significant percentage of the caseload for forensic
and clinical pathologists [2]. AMI is defined in pathology
as myocardial cell death due to prolonged ischemia [3].* Correspondence: hbydcongbin@126.com
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reproduction in any medium, provided the orPatients presenting with symptoms of AMI are often
subject to a standardized battery of tests, including a
radiological examination, an electrocardiogram, and
blood samples submitted for cardiac markers, such as
cardiac troponin (cTn) and creatine kinase MB (CK-MB).
Unfortunately, the postmortem diagnosis of AMI for
forensic and clinical pathologists is difficult. Myocardial
cell death does not occur instantaneously at the onset of
ischemia, but takes at least 6 h before myocardial necrosis
can be identified by standard macroscopic or microscopic
postmortem examination, depending on the sensitivity ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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various techniques have been introduced for postmortem
diagnosis of AMI, currently, there is neither a marker nor
a technique in routine medicolegal use that can solve this
problem satisfactorily [4-6].
S100A1, a dimeric Ca2+-binding protein of the EF-hand
type, belongs to the S100 protein family [7]. As a low
molecular weight protein (~10.5 kDa) with a specific tissue
distribution [8], S100A1 is preferentially abundant in the
heart, especially ventricular cardiomyocytes [9], although it
is also found in lower amounts in skeletal muscle, blood
vessels, brain, and kidney [10-12]. A compelling body of
evidence has disclosed a role for S100A1 as a critical regu-
lator of cardiomyocyte Ca2+ cycling, energy homeostasis,
and excitation-contraction coupling. S100A1 is especially
interesting with respect to cardiovascular diseases because
downregulation of S100A1 protein critically contributes to
the progressive contractile dysfunction of the diseased
heart and cardiac-related death [13,14]. Shortly after ische-
mic myocardial damage in humans, S100A1 appears in the
serum, rising rapidly after the clinical onset [15,16].
Because of S100A1’s specific and differential expression
in the heart and relationship to acute ischemic heart dis-
ease, we tested its performance as a diagnostic indicator of
AMI. In the present study, we constructed a rat myocardial
infarction model to investigate the temporal and spatial dis-
tribution of S100A1 in cardiomyocytes and S100A1 plasma
concentrations after AMI. Immunohistochemical staining
for S100A1 in definite infarction, suspected early infarction,




Healthy Sprague–Dawley rats (250–300 g) of either sex
provided by the Laboratory Animal Department of
Hebei Medical University were used for the study. The
rats were bred and cared for under standard laboratory
conditions, and had ad libitum access to food and water.
All animal procedures were approved by the Institutional
Animal Care and Use Committee. The following groups
of rats were studied to evaluate depletion of S100A1 in
cardiomyocytes and the leakage of cytoplasmic S100A1
into the blood circulation after AMI: (1) sham-operated
group (n = 10); (2) 15 min after left anterior descending
coronary artery (LAD) occlusion (n = 10); (3) 30 min
after LAD occlusion (n = 10); (4) 1 h after LAD occlusion
(n = 10); (5) 2 h after LAD occlusion (n = 10); (6) 4 h
after LAD occlusion (n = 10); and (7) 6 h after LAD oc-
clusion (n = 10).
Experimental induction of myocardial infarction
The animal model of AMI was induced surgically by
permanent ligation of the LAD as previously described[17]. Animals were anesthetized with 350 mg/kg chloral
hydrate, intubated, and ventilated with an animal venti-
lator (Model ALC-V8, China). Following thoracotomy,
the pericardium was carefully opened, avoiding any
injury to the heart, and the LAD was ligated with a
6/0 silk suture by piercing the pericardial membrane.
Successful ligation was tested by visual inspection for
pallor of the involved myocardium and ST segment
elevation ≥0.1 mv on an electrocardiogram. The thorax
was closed in layers, and the lungs were reinflated using
positive end-expiratory pressure. The endotracheal tube
was removed and the animals were returned to normal
respiration. The sham-operated animals were treated
similar to the study groups, except that they did not re-
ceive LAD ligation. After a blood sample was collected,
rats ware humanely sacrificed under general anesthesia
at various ischemia intervals. The hearts were harvested
and fixed in a 4% phosphate-buffered (pH 7.4) formal-
dehyde solution over 24 h. The samples were sequen-
tially dehydrated with an alcohol series and embedded
in paraffin wax. Five-micrometer sections were prepared
from paraffin blocks and stained with hematoxylin and
eosin (H&E).
Autopsy material
Paraffin-embedded myocardial tissue blocks were obtained
from 30 autopsies performed between 2009 and 2013 at
the Department of Forensic Medicine of Hebei Medical
University. The age at autopsy ranged from 22 to 78
years (mean, 51 years) and the postmortem intervals
varied from 8 to 72 h. Myocardial tissues for examination
were taken from the anterior part of the left ventricle,
including the zone of definite or possible infarction. The
cases were divided into three groups as follows. (1)
Group 1 included 10 cases of definite AMI, which was
proven at gross examination (coronary occlusion) and at
conventional histology with H&E (necrotic clotting,
multifocal patches of wavy fibers, contraction band ne-
crosis, and marginal rearrangement reactions with early
inflammatory infiltrate). (2) Group 2 included 10 cases
of acute traumatic death, which were selected among
victims of traffic accidents with immediate lethal cranio-
cerebral injuries or falls from height with no or minimal
signs of coronary atherosclerosis. (3) Group 3 included
10 cases of suspected early myocardial infarction, and
met the following criteria: (i) death occurred within 6 h
from the onset of symptoms, which indicated AMI
clinically; (ii) the subjects had a moderate or severe de-
gree of coronary atherosclerosis at autopsy, but none
of them had macroscopic or microscopic (H&E staining)
evidence of myocardial infarction; and (iii) no other
explainable causes of death were found through a sys-
temic examination, including systemic autopsy and
toxicological analysis.
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To confirm early myocardial ischemic damage, 5-μm
sections were prepared and stained by HBFP staining
[18], which stained ischemic cardiomyocytes crimson
red and normal cardiomyocytes yellow.
Immunohistochemical staining for S100A1
Immunohistochemical staining of 5-μm sections was
performed using the Two-step IHC Detection Reagent
(ZSGB-BIO, China). Briefly, after being treated with
microwave antigen retrieval (0.1 M citrate buffer solution,
pH 6.0) for 5 min, sections were pre-treated with 0.3%
H2O2 in methanol for 30 min to inhibit endogenous
peroxidase activity. Blocking solution with 10% goat
serum (Boster, China) was then applied to the sections
for 30 min at room temperature to minimize non-
specific staining. Subsequently, they were incubated
overnight at 4°C with polyclonal rabbit anti-S100A1
(BS1318, Bioworld, USA) at a dilution of 1:600. PBS
was used to replace S100A1 antibody as the negative
staining control. Labeling was identified by application
of a goat anti-rabbit IgG/horseradish peroxidase sec-
ondary antibody (PV-6001, ZSGB-BIO, China) at 37°C
for 30 min. Peroxidase activity was visualized using a
DAB kit (ZSGB-BIO, China). The reaction was stopped
by rinsing in PBS. Sections were weakly counterstained
with hematoxylin. Finally, the slides were dehydrated,
placed in an aqueous-based mounting medium, and
examined by light microscopy.
Immunoassay for S100A1
Blood samples were collected via retro-orbital sinus
puncture with a capillary tube before rats were sacrificed.
The blood samples were centrifuged at 3000 rpm for
20 min at 4°C, and the serum was then separated and
stored at −80°C until later assay. Serum concentra-
tions of S100A1 were measured using an ELISA kit
(Hebei Bio-high Technology, China) according to the
manufacturer’s protocol. Briefly, 50 μl of the biotinylated
antibody against rat S100A1 and 50 μl of either the di-
luted plasma or the S100A1 standards were added to
the precoated plate. After incubation for 2 h at room
temperature, the wells were washed five times with wash
buffer followed by the addition of 50 μl streptavidin-
HRP. After incubation for an additional 2 h at room
temperature, the washing steps were then repeated as
described above, followed by adding 100 μl of substrate
solution to each well. The microplate was allowed to stand
for 30 min at room temperature in the dark. The reaction
was stopped by adding 50 μl stop solution and the absorb-
ance at 450 nm was measured using an ELx800 Absorb-
ance Microplate Reader (BIO-TEK Instruments, Inc., USA).
S100A1 concentrations for each sample were calculated
from a standard curve.Statistical analysis
Data are described as the median (interquartile range).
Statistical analyses were performed by the Kruskal-Wallis
H test, followed by comparison between any two groups
using SPSS 13.0 software. P values lower than 0.05 were
considered statistically significant.
Results
H&E staining of cardiomyocytes among the groups
The H&E-stained sections of 15 min post AMI showed
conservation of normal morphology of cardiomyocytes,
except for a few cardiomyocytes in the subendocardial
layer and papillary muscles, with a weakly eosinophilic
cytoplasm (Figure 1A). By 2 h after ligation, partial wavy
cardiomyocytes with an eosinophilic cytoplasm were ob-
served in ischemic areas (Figure 2A). By 6 h after ligation,
the H&E-stained sections showed local interstitial edema
and multifocal patches of wavy fibers with increased
eosinophilia of the cytoplasm in ischemic areas.
HBFP staining of cardiomyocytes among the groups for
confirmation of early myocardial damage
Fifteen minutes after ligation, ischemic cardiomyocytes
in the subendocardial layer and papillary muscles were
positively stained crimson in contrast to yellow observed
in nonischemic tissue (Figure 1B). When the ischemic
time was prolonged, the positively stained areas of the heart
expanded and extended to the middle of the myocardium 2
h after ligation (Figure 2B). By 4 h after ligation, crimson
staining was observed in all infarcted myocardial tissue,
which was distinct from normal cardiomyocytes.
Immunohistochemical staining for S100A1 in rat hearts
In the sham-operated group, the cytoplasm of all
cardiomyocytes was stained brown (positive for S100A1)
and the nuclei were stained light blue. The intensity of
staining was uniformly strong and diffusely distributed
in all cardiomyocytes.
In the study groups (AMI model), depletion of S100A1
occurred in a few cardiomyocytes in the subendocardial
layer and papillary muscles 15 min after LAD occlusion
(Figure 1C), which was consistent with the positively
stained areas of HBFP. Thirty minutes after LAD occlusion,
cardiomyocytes with absent S100A1 staining still located in
the subendocardial layer and papillary muscles. Areas of
patchy depletion of S100A1 were larger at 1 h than at
30 min post AMI, and they extended to the middle
myocardium by 2 h post AMI (Figure 2C). By 4 h after
ligation, immunohistochemical staining showed well-
demarcated areas of complete depletion of cytoplasmic
staining of S100A1 in the left ventricle within the LAD sup-
ply region (Figure 3A, B). Six hours after LAD occlusion,
the depleted areas of S100A1 had further expanded with
the prolongation of infarction time.
Figure 1 H&E and HBFP staining, and immunohistochemical staining for S100A1 15 min after ligation. A: The H&E stained sections
showed conservation of normal morphology of cardiomyocytes, except for a few cardiomyocytes in the subendocardial layer and papillary
muscles, with a weakly eosinophilic cytoplasm (bar: 100 μm). B: Ischemic cardiomyocytes in the subendocardial layer and papillary muscles were
positively stained crimson in contrast to yellow for nonischemic cardiomyocytes (HBFP, bar: 100 μm). C: Depletion of S100A1 in a few
cardiomyocytes was detected by IHC, which was in agreement with the positively stained areas of HBFP (bar: 100 μm).
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The time course of plasma concentrations of S100A1 after
AMI is shown in Figure 4. The median plasma S100A1
concentration in the sham-operated group was 81.98 ng/l
(interquartile range: 15.7 ng/l). At 15 min after AMI, the
median S100A1 concentration (192.86 [39.9] ng/l) was
significantly higher than that of the sham-operated group
(P < 0.001). With the continuation of occlusion time,
plasma S100A1 concentrations further increased. Plasma
S100A1 concentrations were 257.27 ng/l (33.19 ng/l),
458.34 ng/l (62.73 ng/l), 622.84 ng/l (53.17 ng/l), and
781.70 ng/l (133.35 ng/l) 30 min, 1 h, 2 h, and 4 h
after LAD occlusion, respectively, and peaked at 6 h
(878.57 ng/l [119.38 ng/l]).
Immunohistochemical staining for S100A1 in human
hearts
In all 10 cases of group 1 with definite infarcted areas,
there was significant depletion of S100A1 in fibrous tissue
and massive depletion in ischemic areas (Figure 5A). In
group 2, strong cytoplasmic S100A1 immunoreactivity
was observed in cardiomyocytes (Figure 5B), althoughFigure 2 H&E and HBFP staining, and immunohistochemical staining
eosinophilic cytoplasm were observed in ischemic areas (bar: 100 μm). B: T
myocardium (bar: 100 μm). C: The positively stained areas of HBFP showedsome staining was light. In group 3, four cases showed
massive depletion of S100A1 expression in ischemic
areas (Figure 5C). Four cases showed patchy depletion of
S100A1 and two cases showed sparse loss in a few
cardiomyocytes. S100A1 immunostaining results in group
3 are shown in Table 1.
Discussion
The most common clinical finding associated with SCD
is coronary artery disease (CAD) and approximately 80%
of SCDs are attributed to this disease condition [19]. An-
other 10% to 15% of SCDs result from cardiomyopathies,
such as hypertrophic cardiomyopathy, arrhythmogenic
right ventricular cardiomyopathy [20], and myocardial
infiltrative diseases. The remaining 5% to 10% are
composed of structurally abnormal congenital cardiac
conditions (i.e., coronary artery abnormalities [21,22]),
cardiac channelopathies and relatively rare diseases
such as cardiac beriberi caused by Thiamine deficiency
[23]. CAD associated with occlusion of one or more major
coronary arteries is likely to result in ventricular tachy-
arrhythmia. This arrhythmia, if untreated, will eventuallyfor S100A1 2 h after ligation. A: Partial wavy cardiomyocytes with
he positively stained areas of HBFP extended to the middle
significant depletion of S100A1 (bar: 100 μm).
Figure 3 Immunohistochemical staining for S100A1 4 h after ligation. Complete depletion of S100A1 in the left ventricle within the LAD
supply region was observed 4 h after LAD occlusion, and this was distinct from normal cardiomyocytes. (A: bar: 1 mm; B: bar: 200 μm).
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lying mechanism in the overwhelming majority of SCDs
[19,24]. AMI is generally the result of CAD. When sudden
death occurs at an early stage of AMI (< 6 h from the onset
of symptoms to death), myocardial cell death cannot easily
be detected by routine histologic techniques, such as H&E
staining. These individuals die before pathological changes
can develop in the myocardium, and it is difficult for the
clinical and forensic pathologists to say with certainty
whether these patients succumbed to AMI.
Irreversible cardiomyocyte injury in AMI can be recog-
nized by the appearance of cardiac proteins in the blood-
stream, which are released into the circulation from injured
cardiomyocytes, because of increased permeability of the
myocardial cell membrane associated with severe ischemiaFigure 4 Boxplot of plasma S100A1 concentrations in rats. The media
ng/l (interquartile range: 15.7 ng/l). At 15 min after AMI, the median S100A
of the sham-operated group (P < 0.001). With the continuation of occlusion[25]. The temporal release pattern of these cellular proteins
is dependent on the extent of hypoxia, their subcellular
localization, and their physicochemical characteristics,
especially molecular weight. Therefore, cellular antigens,
such as MB [4], cTnI [26], and H-FABP [17], can indicate
early myocardial infarction based on the loss of staining in
infarcted areas.
Given the low molecular weight and specific tissue
distribution of S100A1, S100A1 may leak from damaged
cardiomyocytes into the bloodstream of patients with
AMI. Therefore, S100A1 could be used as a “negative
marker” to discern ischemic-damaged myocardial cells
from normal cells, which could be helpful for postmortem
diagnosis of AMI. Previous studies [15,16] have shown that
serum S100A1 concentrations are significantly elevatedn plasma S100A1 concentration in the sham-operated group was 81.98
1 concentration (192.86 [39.9] ng/l) was significantly higher than that
time, plasma S100A1 concentrations further increased.
Figure 5 Immunohistochemical staining for S100A1 in human hearts. A: Massive depletion of H-FABP in ischemic areas was observed (bar:
50 μm). B: Strong cytoplasmic S100A1 immunoreactivity can be seen in normal cardiomyocytes (bar: 50 μm). C: A significant reduction in S100A1
expression in ischemic areas was observed (case 5, bar: 50 μm).
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than MB and cTnI within the early hours (0–6 h) of
the onset of myocardial infarction. The prompt release
of S100A1 into the bloodstream most likely reflects
irreversible changes in cardiomyocytes due to hypoxia.
However, little is known regarding the expression pattern
of S100A1 in ischemic cardiomyocyte lesions.
In the present study, immunohistochemical results of
the AMI animal model showed that as early as 15 min
after myocardial ischemia, S100A1 depletion was detected
in the subendocardial layer and papillary muscles, which
was in agreement with the positively stained areas of HBFP.
When the ischemic time was prolonged, this depletion was
increasingly evident. By 4 h after ligation, the staining
showed well- demarcated areas of complete depletion
of cytoplasmic staining of S100A1 in the left ventricle
within the LAD supply region. Our results showed a time-
dependent depletion of S100A1 after AMI. Additionally,
depletion of S100A1 from cardiomyocytes in infarcted
areas at various post-infarction intervals showed an early
identical pattern with that of H-FABP [17]. These results
strongly suggest that depletion of S100A1 staining inTable 1 Patient characteristics and S100A1 immunostaining r
Case Sex Age (years) Duration of symptoms Postmo
1 M 59 1 h
2 M 22 ?
3 M 55 30 min
4 M 62 45 min
5 M 68 2 h
6 M 58 2.5 h
7 F 64 1 h
8 M 35 1 h
9 M 44 3 h
10 M 48 30 min
☆Grade of coronary atherosclerosis: Grade I: 0–25% of narrowing; Grade II: 25–50%
★Loss of staining is scaled as: massive loss (++); patchy loss (+); loss in a few dissemcardiomyocytes can be used as a sensitive and reliable
marker for AMI.
ELISA results showed a prolonged increase in serum
S100A1 concentrations, providing evidence that S100A1 is
released from injured cardiomyocytes after AMI. Kiewitz
et al. [16] demonstrated that the concentration-time course
of S100A1 is distinct from that of the “classical” biochemical
markers CK, CKMB, and cTnI, showing an early rise and a
fast decline in plasma after the ischemic event. The sensitiv-
ity of S100A1 between 0 and 6 h is significantly higher than
that from 6 to 12 h compared with cTnI. The present study
showed that S100A1 plasma concentrations were low in the
sham-operated group, but they were significantly higher as
early as 15 min after occlusion of the rat LAD than those in
the sham-operated group, indicating its high diagnostic sen-
sitivity for AMI. Moreover, S100A1 plasma concentrations
increased with ischemia, and reached a peak after 6 h, which
was consistent with the results of IHC. This finding suggests
that plasma S100A1 concentrations are in direct proportion
to the extent of ischemic cardiomyocyte injury.
In the autopsy material, the efficacy of S100A1 for
detection of ischemic cardiomyocyte lesions appeared toesults in 10 human heart samples of group 3













; Grade III: 50–75%; Grade IV: >75%.
inated cells (±).
Bi et al. Diagnostic Pathology 2013, 8:84 Page 7 of 7
http://www.diagnosticpathology.org/content/8/1/84be satisfactory. All cases of definite AMI showed well-
defined areas with a significant reduction or total loss of
S100A1 expression. In group 2, eight of 10 cases with the
conclusion of “possible AMI” showed massive or patchy
depletion of S100A1. In only two cases (cases 3 and 10),
because of the short duration from the onset of symptoms
to death (30 min), S100A1 expression was only lost in a
few disseminated cells. These S100A1 immunostaining
results indicated that depletion of S100A1 could be detected
as early as 30 min after ischemic lesions in the human heart.
This finding strongly suggests that depletion of S100A1
from cardiomyocytes is a useful marker for the postmortem
diagnosis of AMI for forensic and clinical pathologists.
No single immunohistochemical reaction is ideal for
the postmortem diagnosis of AMI, and a reasonable
combination of several markers can provide sufficient
evidence of myocardial necrosis, supporting the final
diagnosis. Our study results indicate that evaluation of
immunohistochemical expression of S100A1 can com-
plement the presently used markers to improve the
postmortem diagnosis of AMI.
Conclusions
In conclusion, depletion of S100A1 was observed in ische-
mic cardiomyocytes. The results of this study indicate that
immunohistochemical detection of S100A1 is useful for the
postmortem diagnosis of AMI at an early stage.
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